Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
18.24
+1.13 (6.64%)
At close: Jun 12, 2026, 4:00 PM EDT
19.60
+1.37 (7.49%)
After-hours: Jun 12, 2026, 6:50 PM EDT
Monte Rosa Therapeutics Employees
Monte Rosa Therapeutics had 187 employees as of March 31, 2026. The number of employees increased by 45 or 31.69% compared to the same quarter last year.
Employees
187
Change
45
Growth
31.69%
Revenue / Employee
$229,695
Profits / Employee
-$695,262
Market Cap
1.54B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 187 | 45 | 31.69% |
| Dec 31, 2025 | 150 | 16 | 11.94% |
| Sep 30, 2025 | 147 | 14 | 10.53% |
| Jun 30, 2025 | 142 | 13 | 10.08% |
| Mar 31, 2025 | 142 | 12 | 9.23% |
| Dec 31, 2024 | 134 | 1 | 0.75% |
| Sep 30, 2024 | 133 | 0 | - |
| Jun 30, 2024 | 129 | -4 | -3.01% |
| Mar 31, 2024 | 130 | -3 | -2.26% |
| Dec 31, 2023 | 133 | 10 | 8.13% |
| Sep 30, 2023 | 133 | 15 | 12.71% |
| Jun 30, 2023 | 133 | 29 | 27.88% |
| Mar 31, 2023 | 133 | 38 | 40.00% |
| Dec 31, 2022 | 123 | 30 | 32.26% |
| Sep 30, 2022 | 118 | 24 | 25.53% |
| Jun 30, 2022 | 104 | 21 | 25.30% |
| Mar 31, 2022 | 95 | 35 | 58.33% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Sarepta Therapeutics | 835 |
| AbCellera Biologics | 562 |
| Immunocore Holdings | 524 |
| Syndax Pharmaceuticals | 298 |
| Capricor Therapeutics | 231 |
| Precigen | 160 |
| Septerna | 130 |
GLUE News
- 9 days ago - Monte Rosa Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 10 days ago - Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - Monte Rosa Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 24 days ago - Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Monte Rosa Therapeutics price target raised to $31 from $30 at JPMorgan - TheFly
- 5 weeks ago - Monte Rosa Therapeutics reports Q1 revenue $4.21M, consensus $11.39M - TheFly
- 5 weeks ago - Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - GlobeNewsWire
- 5 weeks ago - Monte Rosa Therapeutics Earnings release: Q1 2026 - Filings